

9 September 2025

Biologics Dermatology

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira:	36
• Adalimumab Biosimilar:	263
• Apremilast:	16
• Bimekizumab:	16
• Brodalumab:	<5
• Certolizumab:	9
• Deucravacitinib:	<5
• Dimethyl fumarate:	<5
• Etanercept – Enbrel:	<5
• Etanercept Biosimilar:	<5
• Guselkumab:	94
• Infliximab – Remicade:	<5
• Infliximab Biosimilar:	11
• Ixekizumab:	60
• Risankizumab:	108
• Secukinumab:	59
• Tildrakizumab:	<5
• Ustekinumab – Stelara:	<5
• Ustekinumab Biosimilar:	80
• Omalizumab:	42
• Spesolimab:	<5

2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

• Adalimumab – Humira:	12
• Adalimumab Biosimilar:	32
• Bimekizumab:	<5
• Certolizumab:	<5
• Infliximab – Remicade:	<5
• Infliximab Biosimilar:	6
• Secukinumab:	12
• Ustekinumab – Stelara:	<5
• Ustekinumab Biosimilar:	<5

9 September 2025

Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.